Publication date: Available online 6 December 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Melody C. Carter, Dean D. Metcalfe, Almudena Matito, Luis Escribano, Joseph H. Butterfield, Lawrence B. Schwartz, Patrizia Bonadonna, Roberta Zanotti, Massimo Triggiani, Mariana Castells, Knut Brockow
Abstract
Providers caring for patients with mastocytosis are tasked with the decision to consider therapeutic options. This may come with some trepidation since the information available in the public domain lists numerous mast cell activators based on data that does not discriminate between primates, rodents and mast cell lines, does not consider dosage and does not take into account previous exposure and resultant clinical findings. This being said, there is support in the literature for an enhanced mast cell response in some patients with mastocytosis and where there is higher incidence of adverse reactions associated with certain antigens such as venoms as well as drugs. This report thus provides a comprehensive guide for those providers who must decide on therapeutic options in the management of patients with clonal mast cell disease.
from Allergy and Immunology via a.sfakia on Inoreader https://ift.tt/2Qm3XSV
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.